InvestorsHub Logo
Followers 164
Posts 36253
Boards Moderated 2
Alias Born 10/20/2019

Re: QuicKtip post# 1001

Wednesday, 05/03/2023 10:48:18 AM

Wednesday, May 03, 2023 10:48:18 AM

Post# of 1295
Looking for $BIXT to tweet or PR about the conference...

About Bioxytran, Inc.

Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, ProLectin-M, is a new class of antiviral drug designed to antagonize galectins in Covid-19, influenza, and respiratory syncytial virus (RSV). ProLectin-I is also a galectin antagonist to target idiopathic pulmonary fibrosis and Long Covid. BXT-25 is an acellular oxygen carrier (AOC) designed to deliver oxygen to hypoxic tissues. Bioxytran’s other development programs are for ischemia of the heart and stroke treatment. More information can be found at www.bioxytraninc.com
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BIXT News